An investigation for investors in NYSE:LCI shares over potential securities laws violations by Lannett Company, Inc. and certain of its directors and officers was announced.
Investors who purchased shares of Lannett Company, Inc. (NYSE:LCI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by Lannett Company, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
According to news reports United States prosecutors may file criminal charges against Lannett Company, Inc. by the end of 2016 for suspected price collusion. It was has reported that the, “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies and about two dozen drugs, according to people familiar with the matter. The grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year, they said.” The companies identified as targets or relevant parties in the United States investigation include Mylan NV, Teva Pharmaceutical Industries Ltd, Allergan Plc, Lannett Co., Impax Laboratories Inc., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo International Plc and Taro Pharmaceutical Industries Ltd.
Shares of Lannett Company, Inc. (NYSE:LCI) closed on November 14, 2016 at $24.25 per share.
Those who purchased NYSE:LCI shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Leave Your Comments